ArticleBMC gastroenterology2025
Impact of metabolic and bariatric surgery on MASLD: histological resolution and metabolic outcomes in a retrospective cohort.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Twelve-Month BMI and Metabolic Changes After Roux-en-Y Gastric Bypass in Women with Severe Obesity.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) involves a spectrum of liver histopathological changes. Obesity is recognized as a risk factor for MASLD. Metabolic and bariatric surgery (MBS) has emerged as a promising therapeutic option.
objectivesTo evaluate the impact of sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) on liver histology, function, and metabolic parameters in patients with obesity and MASLD.
methodsThis retrospective cohort study included patients who met diagnostic criteria of MASLD and underwent MBS between 2013 and 2023. Paired liver biopsies were obtained during the initial surgery and subsequent operations. The primary outcome was histological improvement, assessed by the NAFLD Activity Score (NAS). Secondary outcomes included changes in body weight, liver enzymes, and metabolic parameters.
resultsOf 13 obese patients with histologically confirmed MASLD, the median baseline BMI was 45 [42-50] kg/m², the mean age at the time of surgery was 42 ± 11 years, and 62% were female. Over a mean follow-up of 38 months, patients experienced significant weight loss, with an average total weight loss of 30%. Liver enzymes and metabolic parameters showed marked improvements, including significant reductions in AST, ALT, HbA1c, LDL, and triglyceride levels. Histological analysis revealed that 10 patients (77%) achieved complete resolution of steatohepatitis (NAS = 0), 2 (15%) showed partial improvement, and 1 (8%) remained unchanged. All patients with baseline hepatic fibrosis (54%) demonstrated complete fibrosis resolution. On multivariate analysis, no predictors were significantly associated with postoperative NAS.
conclusionMBS is significantly associated with liver histology and metabolic markers improvement in obese patients with MASLD. High improvement rates support its role as an effective treatment modality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.